New data on the safety of incretin based drug treatments for type 2 diabetes suggests no clear causal role in the development of pancreatic cancer – but could result in a heightened threat of heart failure in patients with increased cardiovascular risk. However a leading Australian endocrinologist has urged clinicians not to abandon the use ...
Expert urges caution on incretins data
By Amanda Sheppeard
29 Feb 2016